In combination with TLR agonists, these ligands can improve vaccine strategies: the delivering of an HPV16 E7 vaccine together with α-galactosylceramide and MPL, a TLR4 agonist, caused an increase in CTL response, lymphocyte proliferation, IFN-γ synthesis and reduction of tumor volume in a C57BL/6 mice tumor model [130]. This evidence concerns the gene IFNG and neoplasm.